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Summary Human endoglin (CD105) is a member of the transforming growth factor beta (TGF-,B) receptor
family that binds TGF-f,1 and -,B3, but not TGF-,B2, on human endothelial cells. Immunohistochemical
analyses demonstrated that CD105 is expressed on normal and neoplastic cells of the melanocytic lineage. The
anti-CD105 MAb, MAEND3, stained 50, 25 and 34% of intradermal naevi, primary and metastatic
melanomas investigated, respectively, and nine out of 12 melanoma cell lines. Sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis revealed that CD105 expressed by melanoma cells
consists of a homodimeric protein with an apparent molecular weight of 180 and 95 kDa under non-reducing
and reducing conditions. Cross-linking of '251-labelled TGF-,B1 to melanoma cells, Mel 97, by disuccinimidyl
suberate (DSS) demonstrated that CD105 expressed on pigmented cells binds TGF-,B1; the pattern of binding
of TGF-f,1 to melanoma cells was found to be similar to that of human umbilical vein endothelial cells. The
addition of exogenous, bioactive TGF-,B1 significantly (P<0.05) inhibited the growth of CD105-positive
melanoma cells, Mel 97, but did not affect that of CD105-negative melanoma cells, FO-1. These data,
altogether, demonstrate that CD105 is expressed on pigmented cells and might play a functionally relevant role
in the biology of human melanoma cells by regulating their sensitivity to TGF-,Bs.
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Human endoglin is a homodimeric membrane glycoprotein of
about 180 kDa, composed of disulphide-linked subunits of
95 kDa (Gougos and Letarte, 1988a). Endoglin is a type I
integral membrane protein with an extracellular region, a
hydrophobic transmembrane domain and a short cytoplasmic
tail (Gougos and Letarte, 1990). The amino acid sequence of
human endoglin, but not that of murine (Ge and Butcher,
1994) and porcine (Yamashita et al,. 1994) species, contains
the tripeptide arginine-glycine-aspartic acid (RGD), which is
located in an exposed region of the extracellular domain
(Gougos and Letarte, 1990). In the course of the fifth.
International Workshop on Leukocyte Differentiation Anti-
gens, endoglin was assigned the cluster of differentiation
(CD) number 105 (Letarte et al., 1995).
CD105 was first identified and characterised on the pre-B
leukaemic cell line HOON (Gougos and Letarte, 1988a,b) by
the murine monoclonal antibody (MAb) 44G4. Additional
studies demonstrated the expression ofCD105 on normal and
neoplastic cells from different hematopoietic lineages
(Quackenbush and Letarte, 1985; Kreindler et al., 1990;
Buhring et al., 1991; Gougos et al., 1992). In addition, by
using MAb 44G4, CD105 was found to be highly expressed
on vascular endothelium from normal tissues and on cultured
human umbilical vein endothelial cells (HUVECs) (Gougos
and Letarte, 1988a). Immunohistochemical analyses per-
formed with the anti-CD105 MAb, PN-E2, on normal,
inflammatory and neoplastic tissues demonstrated that
CD105 is weakly expressed on endothelia from capillary,
venous and arterial blood vessels (Westphal et al., 1993a).
The intensity of staining of endothelia was up-regulated
under proliferative and inflammatory conditions and was
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confined to endothelial cells with a weak reactivity with
fibroblasts, stromal and reticular cells, and with no reactivity
with different neoplastic cell types (Westphal et al., 1993a,b).
These observations, altogether, suggested that CD105 might
be considered a marker of neovascularisation in inflamed and
neoplastic tissues. To the best of our knowledge, no
additional studies have reported on the expression of
CD105 on neoplastic cells from solid tumours.
CD105 belongs to the transforming growth factor # (TGF-
) receptor system (Cheifetz et al., 1992) and has a high
sequence similarity with the transmembrane and cytoplasmic
domains of betaglycan, a TGF-/3-binding protein also known
as TGF-# type III receptor (Lopez-Casillas et al., 1991; Wang
et al., 1991; Moren et al., 1992). Nevertheless, betaglycan
binds all three isoforms of TGF-P, whereas CD105 binds
TGF-#1 and TGF-f,3, but not TGF-f2 (Cheifetz et al., 1992).
The mechanism of action for porcine CD105 has recently
been proposed: following the binding of TGF-f,s, CD105
should form a heteromeric complex with TGF-,B type I and/
or TGF-/ type II receptors that are serine/threonine kinase
receptors with intracellular signalling activity (Yamashita et
al., 1994).
Normal and neoplastic cells of the melanocytic lineage are
differentially susceptible to TGF-/3-mediated growth regula-
tion (le-Ming and Herlyn, 1993; Rodeck, 1993) and little is
known about their expression of TGF-f receptor(s) (Filmus
and Kerbel, 1993; Rodeck et al., 1994). Therefore, in this
study we investigated the expression of CD105 on benign and
malignant cells of the melanocytic lineage and on cultured
melanoma cells. In addition, we analysed the biochemical
structure of CD105 expressed by human melanoma cells.
Lastly, we investigated the ability of CD105 to bind TGF-,Bl
and the growth regulation of CD105-positive and CD105-
negative melanoma cells by TGF-,B1.
We report that: (1) CD105 is expressed in intradermal naevi,
in primary and metastatic melanoma lesions and on cultured
melanoma cells; (2) CD105 expressed by melanoma cells has a
molecular weight of 180 and 95 kDa under non-reducing and
reducing conditions respectively; (3) CD105 expressed onExpression of endoglin in human melanoma
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melanoma cells binds TGF-,B1; and (4) exogenous, bioactive
TGF-fll inhibits the growth ofCD105-positive, but not that of
CD105-negative, melanoma cells.
Material and methods
Monoclonal antibodies and conventional antisera
The anti-CD105 MAb, MAEND3 (IgG1), was generated by
immunising BALB/c mice with TNF-a-treated HUVECs and
characterised for reactivity with human CD105 by sequential
immunodepletion of HUVEC lysates with the anti-CD105
MAb, 44G4 (Gougos and Letarte, 1988a), followed by
immunoprecipitation with MAb, MAEND3, and SDS-
PAGE analysis (M Altomonte, personal communication).
The specificity of MAb, MAEND3, was confirmed during the
fifth International Workshop on Human Leukocyte Antigens
(Letarte et al., 1995). MAb, TS1/22 (mouse IgGI), directed to
leucocyte function-associated antigen-I (LFA-1), which is not
expressed in human melanomas (Altomonte et al., 1993), was
purchased from the American Type Culture Collection
(Rockville, MD, USA). MAbs were purified from ascitic
fluid by sequential precipitation with caprylic acid and
ammonium sulphate (Temponi et al., 1989). The purity of
MAb was tested by SDS-PAGE (Laemmli, 1970) under
reducing and non-reducing conditions.
Dichlorotriazynylaminofluorescein (DTAF)-conjugated
F(ab')2 fragments of goat anti-mouse IgG antibodies, Fc
fragment-specific and AffiniPure rabbit anti-mouse IgG,
Fc fragment-specific were purchased from Jackson
ImmunoResearch Laboratories, Inc. (West Grove, PA, USA).
Tissue samples
Surgical biopsies of benign naevi were obtained from patients
who had undergone reconstructive surgery. Primary and
metastatic lesions were removed from patients who had not
received treatment in the previous 2 months. Each sample was
divided into two portions. One was processed for routine
histopathology and the other one was snap frozen in liquid
nitrogen. From each specimen, 4 jim cryostat sections were
obtained and fixed in absolute acetone for 10 min. Fixed
sections were either used immediately in immunohistochemical
assays or kept frozen at -20°C with no loss of immune
reactivity. Sections stained with 1% toluidine blue were used to
evaluate the histological features of the lesions. Histological
diagnosis was done according to Clark et al. (1972). Tumour
thickness was assessed according to Breslow (1975).
Cells
The human melanoma cell lines, 70-W, Colo 38, FO-1, MeWo
and its highly metastatic variant MeM 50-10, Mel 90, Mel 91,
Mel 97, Mel 99, Mel 100, Mel 109, Mel 116 and the EBV-B
lymphoblastoid cell line JY that lacks CD105 expression
(data not shown), were grown in RPMI-1640 medium (Flow
Laboratories, McLean, VA, USA), supplemented with 10%
heat-inactivated fetal calf serum (FCS) (Flow) and 2 mM L-
glutamine or in W489 medium (Rodeck et al., 1987),
supplemented with 2% FCS, 1% Nutridoma-SR (Boehrin-
ger Mannheim, Milan, Italy) and 2 mM L-glutamine.
HUVECs were obtained by treating umbilical veins with
0.1% DNAase and collagenase (Sigma Chemical Co., St
Louis, MO, USA) for 30 min at 37°C and grown in TC199
medium (Flow), supplemented with 15% FCS, 2 mM L-
glutamine, 24 IU ml-' sodium heparin (Roche, Milan, Italy),
100 jig ml-1 bovine endothelial cell growth supplement
(Sigma), 8% pooled AB serum (Flow) and 100 jg ml-'
gentamycin (Sigma).
Cytokines and reagents
Ultrapure bioactive natural TGF-,B1 was purchased from
Genzyme (Milan, Italy). '25I-labelled TGF-,B1 and [3H]TdR
were purchased from Amersham International (Amersham,
UK). Disuccinimidyl suberate (DSS) was purchased from
Pierce Chemical Co. (Rockford, IL, USA).
Serological assays
Indirect immunofluorescence (IIF) was performed as pre-
viously described (Maio et al., 1990). Samples were analysed
for cell surface fluorescence using a FACScan flow cytometer
(Becton Dickinson Immunocytometry System, Mountain
View, CA, USA) equipped with a model 9135C Hewlett-
Packard computer (Hewlett-Packard, Palo Alto, CA, USA).
Fluorescence was collected by using a four-decade logarith-
mic amplifier. Viable cells (1 x 104, volume gated) were
collected in a list mode fashion for data analysis. The lattpr
was performed with Consort C32 software (Becton-Dick-
inson). Results are expressed as percentage of positive cells
and mean values of fluorescence intensity on a logarithmic
scale. A sample was classified as positive when more than
10% of the cells were stained with the relevant MAb.
Indirect immunoperoxidase stain was performed using
primary MAb at concentrations ranging from 10 -30 jig ml-'
and a commercially available avidin-biotin kit (Vector,
Burlingame, CA, USA). Negative controls consisted of
tissue sections on which the incubation with the primary
antibody was omitted. The stain of endothelial cells of the
vascular wall observable with MAb, MAEND3, provided a
positive control in each specimen studied; in contrast, smooth
muscle cells were not stained by MAb, MAEND3. The
immunoenzymatic reaction was detected using 3-amino-9-
ethycarbazole as a chromogenic substrate and Mayer's
haemotoxylin as nuclear counterstain. Specimens were
scored positive when a specific plasma membrane and/or
cytoplasmic staining pattern could be detected on melanocy-
tic cells, either with a homogeneous or a heterogeneous
distribution.
Radiolabelling of cells, indirect immunoprecipitation and SDS-
PAGE
These were performed as described elsewhere (Maio et al.,
1990). Briefly, cells (2 x 10-7) were labelled with 1251
(Amersham) using the lactoperoxidase method (Zwieg et al.,
1983). Then, cells were solubilised by incubation for 60 min
at 4°C in lysis buffer containing 1% Nonidet P-40 (NP-40)
(Sigma), 10 mM Tris-HCl (pH 8.2), 0.5 M sodium chloride,
1 mM EDTA, 1 mg ml-' BSA, and 1 mM phenylmethylsul-
phonyl fluoride (PMSF) (Sigma), and incubated for 12 h with
the anti-CD105 MAb, MAEND3, bound to Protein A-
Sepharose (Pharmacia), precoated with rabbit anti-mouse Ig
antibody (Fc fragment specific). One dimensional SDS-PAGE
was performed on 10% polyacrylamide slab gels under
reducing and non-reducing conditions using the buffer
system described by Laemmli (1970). Gels were processed
for autoradiography using a Kodak XAR-5 film (Eastman
Kodak Company, Rochester, NY, USA).
Affinity cross-linking of['251I]TGF-131 to melanoma cells
Cross-linking of '251-labelled TGF-,11 to whole melanoma
cells was carried out as described (Massague, 1987) with the
following modifications. Semi-confluent monolayers of
melanoma cells Mel 97 and HUVECs were washed twice
with cold binding buffer (128 mm sodium chloride, 5 mM
potassium chloride, 5 mM magnesium sulphate, 1.2 mM
calcium chloride, 50 mM Hepes, pH 7.5, 2 mg ml-' BSA),
then cells were detached with 1 mM EDTA in PBS for 30 min
at 37°C, washed twice with cold binding buffer and
resuspended (1 x 107) in 500 jil of cold binding buffer. Cell
suspensions of JY cells were washed twice with binding buffer
and resuspended (1 x 10-7) in 500 jil of cold binding buffer.
Cells were then incubated at 4°C with 100 pM [1251]TGF-f3l in
binding buffer in the presence or absence of 10 nM (100-fold
excess) of cold ultrapure natural TGF-,B1, on an orbital
158
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shaker. After a 3 h incubation, cells were washed once with
cold binding buffer and incubated with 0.3 mm (final
concentration) DSS in binding buffer lacking BSA at room
temperature. Following a 15 min incubation, cells were
washed twice with cold binding buffer, resuspended in lysis
buffer and CD105 was immunoprecipitated as described
above. One-dimensional SDS-PAGE was performed on 7.5%
polyacrylamide gels under non-reducing conditions; then gels
were processed as described above.
Cell proliferation assays
Melanoma cell proliferation assays were performed as
described previously (Rodeck et al., 1987). Briefly, melano-
ma cells (5 x 103), Mel 97 and FO-1, grown in complete
W489 medium for at least 2 weeks, were cultured in 96-well
flat-bottom plates (Falcon, Lincoln Park, NJ, USA) in 200 4l
of complete W489 medium. After 24 h, cultures were added
with 25 ng ml-' bioactive TFG-#i. Control cultures were
incubated under the same experimental conditions but
without TGF-#1. After a 16 h incubation at 37°C in a
carbon dioxide humidified atmosphere, cultures were pulsed
with 1 pCi per well of [3H]TdR for 12 h, harvested on glass
fibre strips, and [3H]TdR incorporation was measured by a
MATRIX 96 Direct Beta Counter (Packard, Meridien, CT,
USA).
Statistical analysis
Data were analysed by the Student's paired t-test using the
StatWorks statistical package from Cricket Software
(Philadelphia, PA, USA). Differences with P<0.05 were
considered statistically significant.
Results
Immunohistochemical analysis of CD105 expression in benign
and malignant lesions ofmelanocytic origin
Benign lesions (50%), primary (25%) and metastatic
melanomas (34%) were stained by the anti-CD105 MAb,
MAEND3 (Table I). Within the CD105-positive benign
melanocytic lesions, staining was detected on A-type naevic
cells (Figure la) and junctional areas. Staining of primary
melanomas did not correlate with tumour thickness.
Metastatic melanoma lesions were also reactive with the
anti-CD105 MAb, MAEND3 (Figure lb). In seven lesions
the staining outlined the cell boundaries, while in the
remaining lesions, the antibody reactivity appeared to be
confined to the cytoplasm (Table I. Except for one lesion,
which was homogeneously stained, the majority of the
metastatic cells displayed a variable extent of immunoreac-
tivity ranging from 30-70% (data not shown). Among the
lesions tested no correlation was found between the
expression of CD105 and the anatomical site of malignant
(primary and/or metastatic) lesions (data not shown).
Endothelial cells, but not smooth muscle cells, of blood
Figure 1 Immunohistochemical detection of CD105 by indirect
avidin-biotin immunoperoxidase stain of 4,um acetone-fixed
cryostat sections by MAb MAEND3. Variable levels of CD105
are expressed by A-type naevic cells (a) (arrows mark cells more
strongly stained). Melanoma cells from a metastatic melanoma (b)
display variable degree of expression of CD105 (arrow marks
vessels, arrowheads mark melanin-filled macrophages). Ep,
epidermis. Original magnification x 240.
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Table I Reactivity with anti-CD105 MAb MAEND3 of benign and
malignant lesions of melanocytic origina,b
Type oflesion Positive/tested Staining pattern
Intradermal naevi 5/10 Mostly A-type cells and
junctional areas
Primary melanomasc 3/12 Very weak
Metastatic melanomas 10/29 Weak cell membrane (7)
and cytoplasmic stain (3)
aFour-,um-thick cryostat sections were tested in immunoperoxidase.
bEndothelial cells, but not smooth muscle cells, from blood vessels
within all tested tissue sections were strongly stained by MAb
MAEND3. 'Thickness between 0.4 and 6mm.
Cell lines
Figure 2 Expression of CD105 on human melanoma cell lines.
Melanoma cells (1 x 105) were suspended in PBS-bovine serum
albumin-0.01% sodium azide, and sequentially incubated with
anti-CD105 MAb MAEND3 or the anti-LFA-1 MAb TS1/22 and
with DTAF-conjugated F(ab')2 fragments of goat anti-mouse IgG
xenoantibodies. Then cells (1 x 104, volume gated) were analysed
by flow cytometry. Data represent the percentage of cells stained
by MAb MAEND3 (0), and the values of mean fluorescence
intensity obtained with MAb MAEND3 (0), and with the
isotype-matched MAb TSI/22 (El), used as negative control
primary antibody.
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vessels within all lesions investigated were strongly stained by
the anti-CD105 MAb, MAEND3 (data not shown).
IIF analysis of CD105 expression on melanoma cell lines
IIF staining with the anti-CD105 MAb, MAEND3, showed a
heterogeneous expression ofCD105 on the melanoma cell lines,
70-W, Colo 38, FO-1, MeWo, MeM 50-10, Mel 90, Mel 91, Mel
97, Mel 99, Mel 100, Mel 109 and Mel 116 (Figure 2). The
percentage of stained cells ranged from 36-89% for Colo 38
and Mel 91 melanoma cells respectively. The values of mean
fluorescence intensity, which are an indirect expression of
antigen density, ranged from 7 to 25 for melanoma cells, Colo
38 and Mel 97, respectively. The anti-CD105 MAb, MAEND3,
stained less than 10% ofcells from the melanoma cell lines, FO-
1, Mel 90 and Mel 99 (Figure 2). In contrast, MAb, MAEND3,
stained 100% of HUVECs with a value of mean fluorescence
intensity of 313 (Figure 2).
Molecular profile of CD105 expressed by melanoma cells
SDS-PAGE analysis demonstrated that the anti-CD105
MAb, MAEND3, immunoprecipitated components with a
molecular weight of about 180 kDa and 95 kDa under non-
reducing and reducing conditions, respectively, from radi-
olabelled melanoma cell lines, Mel 91, Mel 97 and 70-W
(Figure 3). Components with a similar molecular weight were
immunoprecipitated by MAb, MAEND3, from radiolabelled
HUVECs (Figure 3). SDS-PAGE analysis of immunopreci-
pitates from melanoma cells, FO-1, did not identify
components with a molecular weight similar to those
obtained for the other melanoma cell lines investigated
(Figure 3).
Binding of '25I-labelled TGF-f,B to CD105 expressed on
melanoma cells
Cross-linking by DSS of '251-labelled TGF-,11 to melanoma
cells, Mel 97, and HUVECs followed by immunoprecipitation
with an anti-CD105 MAb, MAEND3, demonstrated that
CD105 expressed on pigmented cells binds TGF-,B1. Figure 4
shows that the molecular weight of the complex '25I-labelled
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TGF-,Bl-CD105 immunoprecipitated by MAb, MAEND3,
from melanoma cells was about 200 kDa (lane 4) and similar
to that immunoprecipitated from HUVECs (lane 2). The
binding of '25I-labelled TGF-#1 to melanoma cells was
completely inhibited by the addition of a 100-fold excess of
cold TGF-,B1 (lane 5); the latter concentration of cold TGF-
,31 did not completely inhibit the binding of radiolabelled
TGF-#1 to HUVECs (lane 3). An additional band of about
300 kDa was detectable following cross-linking of 1251.
labelled TGF-#1 to melanoma cells (lane 4) and HUVECs
(lane 2) by DSS. The intensity of the latter component
decreased for both melanoma cells (lane 5) and HUVECs
(lane 3) in the presence of cold TGF-#1. Opposite to
melanoma cells and HUVECs, 1251I-labelled TGF-,11 did not
bind to EBV-B cells, JY (Figure 4, lanes 6 and 7), that do not
express CD105 (data not shown).
Growth inhibition ofmelanoma cells by exogenous bioactive
TGF-fI
The addition of bioactive TGF-fl (25 ng ml-') to cultures of
melanoma cells significantly (P<0.05) inhibited the growth of
CD105-positive melanoma cells, Mel 97, but did not affect
that of CD105-negative melanoma cells, FO-1. Figure 5 shows
the mean value ofinhibition of[3H]TdR uptake by melanoma
cells from three experiments.
Discussion
Immunohistochemical analyses demonstrated that CD105 is
expressed inbenign andmalignantlesions ofmelanocytic origin
and on cultured melanoma cells. This observation represents
the first report demonstrating the expression of CD105 on
pigmented cells and the presence of an RGD-containing
Cold TGF-13l
kDa
- 200
- 97
-69
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1 2 3 4 51
Non-reducing
1 2 3 4 5
Reducing
Figure 3 SDS-PAGE analysis of antigens immunoprecipitated
by the anti-CD105 MAb MAEND3 from melanoma cell lines and
HUVEC. Melanoma cell lines Mel 91 (lane 2), Mel 97 (lane 3),
70-W (lane 4) and FO-I (lane 5) and HUVEC (lane 1) were
radiolabelled with 125I and solubilised with lysis buffer. Following
indirect immunoprecipitation with MAb MAEND3, the antigens
were eluted from immunoadsorbent and analysed by SDS-PAGE
in a 10% slab gel under non-reducing and reducing conditions.
Gels were then processed for autoradiography.
Figure 4 SDS-PAGE analysis of the 125I-labelled-TGF-f3I-
CD105 complex immunoprecipitated from HUVEC, Mel 97 and
JY cells. 125I-labelled TGF-,B1 was cross-linked to HUVEC (lanes
2 and 3), Mel 97 melanoma cells (lanes 4 and 5) and EBV-B cells
JY (lanes 6 and 7) by DSS in the presence (+) or absence (-) of
a 100-fold excess ofcold TGF-f,l. Cells were then solubilised with
lysis buffer. Following indirect immunoprecipitation with the anti-
CD105 MAb MAEND3, the antigens were eluted from
immunoadsorbent and analysed by SDS-PAGE in a 7.5% slab
gel under non-reducing conditions. Gels were then processed for
autoradiography. Lane 1 shows CD105 immunoprecipitated by
MAb MAEND3 from 1251-radiolabelled HUVEC.Expression of endoglin in human melanoma
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Mel 97
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Figure 5 Growth inhibition of melanoma cells, Mel 97 and FO-1,
by exogenous bioactive TGF-fl. Melanoma cells (5 x 103) were
plated in triplicate in 96-well plates and 25ngml-1 TGF-131 was
added. Control cultures were treated under similar experimental
conditions but without stimuli. After a 16h incubation, cultures
were pulsed for 12h with 1 ,uCi per well [3H]TdR, harvested and
incorporated radioactivity was measured by a beta counter. Data
represent the mean values +s.d. of three experiments. *P<0.05 vs
control.
molecule on the cell surface of human cells of the melanocytic
lineage. The expression of CD105 that we observed with the
anti-CD105 MAb, MAEND3, is at variance with a previous
report in which melanocytic cells were not stained by the anti-
CD105, MAb, PN-E2 (Westphal et al., 1993b). This
discrepancy is probably due to a different affinity of the two
anti-CD105 MAbs, since MAb, PN-E2, weakly stained
endothelial cells (Westphal et al., 1993a,b) that were strongly
stained by the anti-CD105 MAb, 44G4 (Gougos and Letarte,
1988a) and by our MAb, MAEND3 (Figure 2).
SDS-PAGE performed under non-reducing conditions
demonstrated that the molecular weight of CD105 expressed
on melanoma cells is identical to that observed for
endothelial cells. In addition, as previously reported for
endothelial and lymphoid cells (Gougos and Letarte, 1988a),
the analysis of the components immunoprecipitated by the
anti-CD105 MAb, MAEND3, under reducing conditions
revealed that CD105 expressed by melanoma cells consists of
two subunits with an identical molecular weight of 95 kDa.
The structural similarity of the components immunoprecipi-
tated from the melanoma cell lines, Mel 91, Mel 97 and 70-
W, suggests the absence of molecular heterogeneity for
CD105 expressed by different melanoma cells. In addition,
the similarity of CD105 expressed on HUVECs and
melanoma cells suggests that malignant transformation does
not affect the molecular structure of the molecule.
Several studies have shown that melanocytes secrete TGF-
,B1 and TGF-#3, that melanoma cells secrete all three
isoforms of TGF-,B (le-Ming and Herlyn, 1993; Rodeck,
1993; Filmus and Kerbel, 1993; Reed et al., 1994) and that
both cell types can be growth-inhibited by TGF-f,1 (le-Ming
and Herlyn, 1993; Rodeck, 1993; Filmus and Kerbel, 1993).
Nevertheless, little is known about the expression of the
TGF-3 receptor complex on melanocytes and melanoma
cells. Rodeck et al. (1994) have recently shown by cross-
linking of radiolabelled '25I-TGF-fi1 to cells that the
melanoma cell line WM164 co-expresses TGF-# type I and
type III receptors. In this study we report that melanocytic
cells express CD105, which has been shown to present TGF-
f,s to TGF-,B type I and/or type II receptors (ten Dijke et al,.
1994; Yamashita et al., 1994). In addition, we demonstrate
that CD105 expressed by melanoma cells binds TGF-#1. In
fact, following cross-linking of 1251-labelled TGF-#1 to
melanoma cells by DSS, MAb, MAEND3, immunoprecipi-
tated a component with a molecular weight of about
200 kDa. This shift in the molecular weight of CD105 is
compatible with its binding to TGF-,B1 and the molecular
weight of the complex is similar to that reported for the
complex CD105-TGF-,ll immunoprecipitated from HU-
VECs using the anti-CD105 MAb 44G4 (Letarte et al.,
1995) and MAb MAEND3 in this study (Figure 4, lane 2).
This 200 kDa band was completely abolished in immunopre-
cipitates of melanoma cells (Figure 4, lane 5), but not of
HUVECs (Figure 4, lane 3), when cells were cross-linked with
251I-labelled TGF-,B1 by DSS in the presence of competing
cold TGF-fl. The latter discrepancy is probably caused by
the lower amounts of CD105 expressed on melanoma cells
compared with HUVECs (Figure 2).
SDS-PAGE analysis of the components immunoprecipi-
tated by MAb MAEND3 following cross-linking of 1251_
labelled TGF-fll to melanoma cells by DSS identified an
additional band of about 300 kDa. The latter is likely to
represent an oligomer of CD105 being similar to that
reported for HUVECs using MAb 44G4 (Letarte et al.,
1995) and MAb MAEND3 (Figure 4).
Our cross-linking studies did not identify additional
components suggestive for the presence of TGF-,B type I
and type II receptors in the immunoprecipitates performed
with MAb MAEND3, either in melanoma or in HUVECs.
This finding is at variance with the demonstration provided
by Yamashita et al. (1994) that an antiserum raised to the
intracytoplasmic domain of porcine CD105 immunoprecipi-
tates TGF-,B type I and type II receptors from porcine aortic
endothelial cells cross-linked to '251-labelled TGF-fll by
dithiothreitol. Nevertheless, the intensity of the components
corresponding to TGF-,B and type I and type II receptors was
much stronger when immunoprecipitation was performed
with an antiserum to TGF-,B type II receptor. In addition to
differences in experimental conditions, several factors may
explain the discrepancy between the two studies including:
the cell types analysed by Yamashita et al. (1994) and
ourselves; the type of anti-CD105 antibodies used in the two
studies; and their recognition of intracellular or extracellular
domains of the molecule. The lack of detection of TGF-,B1
type I and type II receptors in immunoprecipitates of
melanoma cells may also be explained by their low
expression of CD105, and by the suggestion that only a
fraction of CD105 is associated with TGF-,B type I and type
II receptors (Zhang et al., 1996). The lack of detection of
TGF-,B type I and type II receptors in the immunoprecipitates
of HUVECs cross-linked to 1251I-labelled TGF-f,l by DSS
(Figure 4) is consistent with the data reported with HUVECs
using different MAbs to human CD105 (Letarte et al., 1995),
and suggests that the complex composed of CD105 and
TGF-# type I and type II receptors is not readily detectable
in HUVECs as compared with porcine endothelial cells
(Yamashita et al., 1994). A similar finding has recently been
reported by HUVECs as compared with pre-B cells by Zhang
et al. (1996).
The differential effect of exogenous, bioactive TGF-,B1 in
the growth inhibition of CD105-positive melanoma cells, Mel
97, as compared with CD105-negative melanoma cells, FO-1
suggests that CD105 contributes to the regulation of the
antiproliferative effect of TGF-,B1 on melanoma cells.
The identification of CD105 on normal and neoplastic
cells of the melanocytic lineage helps to dissect the
complexity of the TGF-,B receptor system on pigmented
cells. The ability of CD105 to bind TGF-f1 further supports
the functional role of TGF-fls in pigmented cells.
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